The second also comprises four miRs (miR-155, miR-27a, miR-30e, and miR-493) and is linked to BC classification based on ER/PR/HER2/basal cytokeratin/EGFR status as well as separation of cases into low- and high-risk categories (50) with the ability to predict patient response to therapy with the two most common systemic protocols used to treat TNBC (anthracycline or anthracycline plus taxanes) (146). The gene discussed is ESR1; the disease is breast cancer.